OBJECTIVE: We investigated the effect of short viremic episodes on soluble markers associated with endothelial stress and cardiovascular disease risk in chronically HIV-1-infected patients followed during continuous antiretroviral therapy, antiretroviral therapy interruption and antiretroviral therapy resumption. DESIGN AND METHODS: We assessed changes in plasma levels of von Willebrand factor, soluble vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 by enzyme-linked immunosorbent assay, as well as T-cell activation (CD8+/CD38+, CD8+/HLA-DR+ and CD3+/CD95+) by flow cytometry, in 36 chronically HIV-1-infected patients participating in a randomized study. Patients were divided into the following three groups: a, on continuous antiretroviral therapy; b, on a 6-week antiretroviral therapy interruption; or c, on antiretroviral therapy interruption extended to the achievement of viral set point. RESULTS: Although all measurements remained stable over a 40-week follow-up on antiretroviral therapy, plasma levels of soluble vascular cell adhesion molecule-1 (P < 0.0001) and soluble intercellular adhesion molecule-1 (P = 0.003) increased during treatment interruption in correlation with viral rebound and T-cell activation. No significant changes in von Willebrand factor were observed in any of the groups. After resuming antiretroviral therapy, soluble vascular cell adhesion molecule-1 levels remained elevated even after achievement of viral suppression to less than 50 copies/ml. CONCLUSION: The prompt rise in plasma soluble vascular cell adhesion molecule-1 and soluble intercellular adhesion molecule-1 upon viral rebound suggests an acute increase in endothelial stress upon treatment interruption, which may persists after viral resuppression of virus. Thus, viral replication during short-term treatment interruption may increase the overall cardiovascular risk during and beyond treatment interruption.
RCT Entities:
OBJECTIVE: We investigated the effect of short viremic episodes on soluble markers associated with endothelial stress and cardiovascular disease risk in chronically HIV-1-infectedpatients followed during continuous antiretroviral therapy, antiretroviral therapy interruption and antiretroviral therapy resumption. DESIGN AND METHODS: We assessed changes in plasma levels of von Willebrand factor, soluble vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 by enzyme-linked immunosorbent assay, as well as T-cell activation (CD8+/CD38+, CD8+/HLA-DR+ and CD3+/CD95+) by flow cytometry, in 36 chronically HIV-1-infectedpatients participating in a randomized study. Patients were divided into the following three groups: a, on continuous antiretroviral therapy; b, on a 6-week antiretroviral therapy interruption; or c, on antiretroviral therapy interruption extended to the achievement of viral set point. RESULTS: Although all measurements remained stable over a 40-week follow-up on antiretroviral therapy, plasma levels of soluble vascular cell adhesion molecule-1 (P < 0.0001) and soluble intercellular adhesion molecule-1 (P = 0.003) increased during treatment interruption in correlation with viral rebound and T-cell activation. No significant changes in von Willebrand factor were observed in any of the groups. After resuming antiretroviral therapy, soluble vascular cell adhesion molecule-1 levels remained elevated even after achievement of viral suppression to less than 50 copies/ml. CONCLUSION: The prompt rise in plasma soluble vascular cell adhesion molecule-1 and soluble intercellular adhesion molecule-1 upon viral rebound suggests an acute increase in endothelial stress upon treatment interruption, which may persists after viral resuppression of virus. Thus, viral replication during short-term treatment interruption may increase the overall cardiovascular risk during and beyond treatment interruption.
Authors: Irene M van der Meer; Moniek P M de Maat; Michiel L Bots; Monique M B Breteler; John Meijer; Amanda J Kiliaan; Albert Hofman; Jacqueline C M Witteman Journal: Arterioscler Thromb Vasc Biol Date: 2002-05-01 Impact factor: 8.311
Authors: E Papasavvas; G M Ortiz; R Gross; J Sun; E C Moore; J J Heymann; M Moonis; J K Sandberg; L A Drohan; B Gallagher; J Shull; D F Nixon; J R Kostman; L J Montaner Journal: J Infect Dis Date: 2000-08-17 Impact factor: 5.226
Authors: M Erren; H Reinecke; R Junker; M Fobker; H Schulte; J O Schurek; J Kropf; S Kerber; G Breithardt; G Assmann; P Cullen Journal: Arterioscler Thromb Vasc Biol Date: 1999-10 Impact factor: 8.311
Authors: Susan M Graham; Nimerta Rajwans; Walter Jaoko; Benson B A Estambale; R Scott McClelland; Julie Overbaugh; W Conrad Liles Journal: AIDS Date: 2013-07-17 Impact factor: 4.177
Authors: Roksana Karim; Wendy J Mack; Naoko Kono; Phyllis C Tien; Kathryn Anastos; Jason Lazar; Mary Young; Seema Desai; Elizabeth T Golub; Robert C Kaplan; Howard N Hodis; Andrea Kovacs Journal: J Acquir Immune Defic Syndr Date: 2014-11-01 Impact factor: 3.731
Authors: Clarisa M Buckner; Susan Moir; Jason Ho; Wei Wang; Jacqueline G Posada; Lela Kardava; Emily K Funk; Amy K Nelson; Yuxing Li; Tae-Wook Chun; Anthony S Fauci Journal: J Virol Date: 2013-03-13 Impact factor: 5.103
Authors: Emmanouil Papasavvas; Maxwell Pistilli; Griffin Reynolds; Robert Bucki; Livio Azzoni; Jihed Chehimi; Paul A Janmey; Mark J DiNubile; Joe Ondercin; Jay R Kostman; Karam C Mounzer; Luis J Montaner Journal: AIDS Date: 2009-01-28 Impact factor: 4.177